Suppr超能文献

减肥饮食对高血压患者的长期影响。

Long-term effects of weight-reducing diets in people with hypertension.

机构信息

Institute of General Practice and Evidence-Based Health Services Research, Medical University of Graz, Graz, Austria.

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

出版信息

Cochrane Database Syst Rev. 2021 Feb 8;2(2):CD008274. doi: 10.1002/14651858.CD008274.pub4.

Abstract

BACKGROUND

All major guidelines for antihypertensive therapy recommend weight loss. Dietary interventions that aim to reduce body weight might therefore be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension.

OBJECTIVES

Primary objectives To assess the long-term effects of weight-reducing diets in people with hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (including total serious adverse events, withdrawal due to adverse events, and total non-serious adverse events). Secondary objectives To assess the long-term effects of weight-reducing diets in people with hypertension on change from baseline in systolic blood pressure, change from baseline in diastolic blood pressure, and body weight reduction.

SEARCH METHODS

For this updated review, the Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to April 2020: the Cochrane Hypertension Specialised Register, CENTRAL (2020, Issue 3), Ovid MEDLINE, Ovid Embase, and ClinicalTrials.gov. We also contacted authors of relevant papers about further published and unpublished work. The searches had no language restrictions.

SELECTION CRITERIA

We included randomised controlled trials (RCTs) of at least 24 weeks' duration that compared weight-reducing dietary interventions to no dietary intervention in adults with primary hypertension.

DATA COLLECTION AND ANALYSIS

Two review authors independently assessed risks of bias and extracted data. Where appropriate and in the absence of significant heterogeneity between studies (P > 0.1), we pooled studies using a fixed-effect meta-analysis. In case of moderate or larger heterogeneity as measured by Higgins I, we used a random-effects model.

MAIN RESULTS

This second review update did not reveal any new trials, so the number of included trials remains the same: eight RCTs involving a total of 2100 participants with high blood pressure and a mean age of 45 to 66 years. Mean treatment duration was 6 to 36 months. We judged the risks of bias as unclear or high for all but two trials. No study included mortality as a predefined outcome. One RCT evaluated the effects of dietary weight loss on a combined endpoint consisting of the necessity of reinstating antihypertensive therapy and severe cardiovascular complications. In this RCT, weight-reducing diet lowered the endpoint compared to no diet: hazard ratio 0.70 (95% confidence interval (CI) 0.57 to 0.87). None of the trials evaluated adverse events as designated in our protocol. The certainty of the evidence was low for a blood pressure reduction in participants assigned to weight-loss diets as compared to controls: systolic blood pressure: mean difference (MD) -4.5 mm Hg (95% CI -7.2 to -1.8 mm Hg) (3 studies, 731 participants), and diastolic blood pressure: MD -3.2 mm Hg (95% CI -4.8 to -1.5 mm Hg) (3 studies, 731 participants). We judged the certainty of the evidence to be high for weight reduction in dietary weight loss groups as compared to controls: MD -4.0 kg (95% CI -4.8 to -3.2) (5 trials, 880 participants). Two trials used withdrawal of antihypertensive medication as their primary outcome. Even though we did not consider this a relevant outcome for our review, the results of these RCTs strengthen the finding of a reduction of blood pressure by dietary weight-loss interventions.

AUTHORS' CONCLUSIONS: In this second update, the conclusions remain unchanged, as we found no new trials. In people with primary hypertension, weight-loss diets reduced body weight and blood pressure, but the magnitude of the effects are uncertain due to the small number of participants and studies included in the analyses. Whether weight loss reduces mortality and morbidity is unknown. No useful information on adverse effects was reported in the relevant trials.

摘要

背景

所有主要的降压治疗指南都建议减肥。因此,旨在减轻体重的饮食干预可能是降低血压和与高血压相关的不良心血管事件的有用干预措施。

目的

主要目的评估减肥饮食对高血压患者的全因死亡率、心血管发病率和不良事件(包括总严重不良事件、因不良事件退出和总非严重不良事件)的长期影响。次要目的评估减肥饮食对高血压患者的收缩压从基线变化、舒张压从基线变化和体重减轻的长期影响。

搜索方法

对于本次更新的综述,Cochrane 高血压信息专家在 Cochrane 高血压特藏、CENTRAL(2020 年第 3 期)、Ovid MEDLINE、Ovid Embase 和 ClinicalTrials.gov 中搜索了截至 2020 年 4 月的随机对照试验。我们还联系了相关论文的作者,了解进一步发表和未发表的工作。搜索没有语言限制。

入选标准

我们纳入了至少持续 24 周的随机对照试验(RCT),比较了原发性高血压成人中减肥饮食干预与无饮食干预的效果。

数据收集和分析

两名综述作者独立评估了偏倚风险并提取了数据。如果适当且研究之间没有显著的异质性(P > 0.1),我们使用固定效应荟萃分析对研究进行了合并。如果用 Higgins I 测量存在中度或更大的异质性,则使用随机效应模型。

主要结果

本次第二更新未发现任何新试验,因此纳入的试验数量保持不变:八项 RCT 共涉及 2100 名高血压患者,平均年龄为 45 至 66 岁。平均治疗时间为 6 至 36 个月。我们判断除了两项试验之外,所有试验的偏倚风险都不明确或很高。没有研究将死亡率作为预设结局。一项 RCT 评估了饮食减肥对由需要重新开始抗高血压治疗和严重心血管并发症组成的复合终点的影响。在这项 RCT 中,与不节食相比,节食降低了终点:风险比 0.70(95%置信区间(CI)0.57 至 0.87)。没有一项试验将不良事件作为我们方案中指定的结局进行评估。与对照组相比,减肥饮食对参与者血压降低的证据确定性为低:收缩压:平均差值(MD)-4.5mmHg(95%CI-7.2 至-1.8mmHg)(3 项研究,731 名参与者),舒张压:MD-3.2mmHg(95%CI-4.8 至-1.5mmHg)(3 项研究,731 名参与者)。我们判断减肥饮食组体重减轻的证据确定性为高:MD-4.0kg(95%CI-4.8 至-3.2)(5 项研究,880 名参与者)。两项试验将停止使用抗高血压药物作为其主要结局。尽管我们认为这不是我们综述的相关结局,但这些 RCT 的结果加强了饮食减肥干预降低血压的发现。

作者结论

在本次第二更新中,结论保持不变,因为我们没有发现新的试验。在原发性高血压患者中,减肥饮食可降低体重和血压,但由于纳入分析的参与者和研究数量较少,其效果的幅度仍不确定。减肥是否降低死亡率和发病率尚不清楚。相关试验未报告有关不良影响的有用信息。

相似文献

1
Long-term effects of weight-reducing diets in people with hypertension.
Cochrane Database Syst Rev. 2021 Feb 8;2(2):CD008274. doi: 10.1002/14651858.CD008274.pub4.
2
Long-term effects of weight-reducing diets in people with hypertension.
Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD008274. doi: 10.1002/14651858.CD008274.pub3.
3
Long-term effects of weight-reducing diets in hypertensive patients.
Cochrane Database Syst Rev. 2011 Sep 7(9):CD008274. doi: 10.1002/14651858.CD008274.pub2.
4
Long-term effects of weight-reducing drugs in people with hypertension.
Cochrane Database Syst Rev. 2021 Jan 17;1(1):CD007654. doi: 10.1002/14651858.CD007654.pub5.
6
Long-term effects of weight-reducing drugs in people with hypertension.
Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4.
7
Blood pressure targets in adults with hypertension.
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. doi: 10.1002/14651858.CD004349.pub3.
8
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
Cochrane Database Syst Rev. 2020 Sep 9;9(9):CD010315. doi: 10.1002/14651858.CD010315.pub4.
9
Withdrawal of antihypertensive drugs in older people.
Cochrane Database Syst Rev. 2020 Jun 10;6(6):CD012572. doi: 10.1002/14651858.CD012572.pub2.
10
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170. doi: 10.1002/14651858.CD008170.pub3.

引用本文的文献

1
Effects of a two-night hospitalization program as a specific health guidance on obesity and cardiovascular disease risk factors.
J Gen Fam Med. 2025 May 19;26(5):442-450. doi: 10.1002/jgf2.70031. eCollection 2025 Sep.
4
Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.
Can Fam Physician. 2025 Jul 29;71(7-8):467-482. doi: 10.46747/cfp.20250616001.
5
[Not Available].
CMAJ. 2025 Jun 15;197(23):E656-E673. doi: 10.1503/cmaj.241770-f.
6
Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.
Can Pharm J (Ott). 2025 May 27:17151635251343907. doi: 10.1177/17151635251343907.
8
Which is more effective in hypertension?: Salt-free diet vs DASH diet.
Medicine (Baltimore). 2025 Mar 7;104(10):e41636. doi: 10.1097/MD.0000000000041636.
9
Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement.
J Hum Hypertens. 2025 Jan;39(1):1-14. doi: 10.1038/s41371-024-00983-6. Epub 2024 Dec 9.
10
Semaglutide and blood pressure: an individual patient data meta-analysis.
Eur Heart J. 2024 Oct 7;45(38):4124-4134. doi: 10.1093/eurheartj/ehae564.

本文引用的文献

3
Effectiveness of an App and Provider Counseling for Obesity Treatment in Primary Care.
Am J Prev Med. 2018 Dec;55(6):777-786. doi: 10.1016/j.amepre.2018.07.005. Epub 2018 Oct 22.
4
Association between lifestyle risk factors and incident hypertension among middle-aged and older Australians.
Prev Med. 2019 Jan;118:73-80. doi: 10.1016/j.ypmed.2018.10.007. Epub 2018 Oct 12.
5
2018 ESC/ESH Guidelines for the management of arterial hypertension.
Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
9
10
Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial.
Am J Clin Nutr. 2017 Jul;106(1):35-43. doi: 10.3945/ajcn.117.153270. Epub 2017 May 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验